Basilea Pharmaceutica Forecast, price target & analysts
Basilea Pharmaceutica Target price 2025 - Analyst rating & recommendation
Basilea Pharmaceutica Classifications & Recommendation:
Basilea Pharmaceutica Price Target
| Target Price | CHF91.49 |
| Price | CHF47.60 |
| Potential |
92.21%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Basilea Pharmaceutica 2026 .
The average Basilea Pharmaceutica target price is CHF91.49.
This is
92.21%
register free of charge
CHF126.00
164.71%
register free of charge
CHF64.64
35.80%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Basilea Pharmaceutica to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Basilea Pharmaceutica stock has an average upside potential 2026 of
92.21%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 208.54 | 220.79 |
| 32.30% | 5.87% | |
| EBITDA Margin | 30.17% | 26.16% |
| 128.84% | 13.28% | |
| Net Margin | 37.21% | 22.38% |
| 461.23% | 39.85% |
9 Analysts have issued a sales forecast Basilea Pharmaceutica 2025 . The average Basilea Pharmaceutica sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Basilea Pharmaceutica EBITDA forecast 2025. The average Basilea Pharmaceutica EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Basilea Pharmaceutica Analysts have issued a net profit forecast 2025. The average Basilea Pharmaceutica net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 5.60 | 4.09 |
| 543.68% | 26.96% | |
| P/E | 11.64 | |
| EV/Sales | 2.53 |
9 Analysts have issued a Basilea Pharmaceutica forecast for earnings per share. The average Basilea Pharmaceutica EPS is
This results in the following potential growth metrics and future valuations:
Basilea Pharmaceutica...
Current Basilea Pharmaceutica Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Dec 22 2024 |
| BRYAN GARNIER |
Locked
➜
Locked
|
Locked | Dec 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Dec 22 2024 |
|
Locked
BRYAN GARNIER:
Locked
➜
Locked
|
Dec 15 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
